Paul W Burridge

List of Publications by Year
in descending order

75 papers	7,153 citations	101496 36 h-index	82499 72 g-index
80 all docs	80 docs citations	80 times ranked	9417 citing authors

#	Article	IF	Citations
1	Chemically defined generation of human cardiomyocytes. Nature Methods, 2014, 11, 855-860.	9.0	1,320
2	Production of De Novo Cardiomyocytes: Human Pluripotent Stem Cell Differentiation and Direct Reprogramming. Cell Stem Cell, 2012, 10, 16-28.	5.2	616
3	Human induced pluripotent stem cellâ€“derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nature Medicine, 2016, 22, 547-556.	15.2	573
4	A Universal System for Highly Efficient Cardiac Differentiation of Human Induced Pluripotent Stem Cells That Eliminates Interline Variability. PLoS ONE, 2011, 6, e18293.	1.1	363
5	A physical map of the mouse genome. Nature, 2002, 418, 743-750.	13.7	316
6	High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Science Translational Medicine, 2017, 9, .	5.8	297
7	Improved Human Embryonic Stem Cell Embryoid Body Homogeneity and Cardiomyocyte Differentiation from a Novel V-96 Plate Aggregation System Highlights Interline Variability. Stem Cells, 2007, 25, 929-938.	1.4	275
8	Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cellâ€“Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays. Circulation, 2013, 128, S3-13.	1.6	269
9	Human Stem Cells for Modeling Heart Disease and for Drug Discovery. Science Translational Medicine, 2014, 6, 239ps6.	5.8	175
10	Human Induced Pluripotent Stem Cellâ€“Derived Cardiomyocytes as an In Vitro Model for Coxsackievirus B3â€“Induced Myocarditis and Antiviral Drug Screening Platform. Circulation Research, 2014, 115, 556-566.	2.0	134
11	Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses InÂVitro. Cell Stem Cell, 2016, 19, 311-325.	5.2	131
12	MicroRNA-302 Increases Reprogramming Efficiency via Repression of NR2F2. Stem Cells, 2013, 31, 259-268.	1.4	121
13	A Review of Human Pluripotent Stem Cell-Derived Cardiomyocytes for High-Throughput Drug Discovery, Cardiotoxicity Screening, and Publication Standards. Journal of Cardiovascular Translational Research, 2013, 6, 22-30.	1.1	114
14	Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells. Current Protocols in Human Genetics, 2015, 87, 21.3.1-21.3.15.	3.5	112
15	Passive Stretch Induces Structural and Functional Maturation of Engineered Heart Muscle as Predicted by Computational Modeling. Stem Cells, 2018, 36, 265-277.	1.4	111
16	Molecular Imaging of Stem Cells: Tracking Survival, Biodistribution, Tumorigenicity, and Immunogenicity. Theranostics, 2012, 2, 335-345.	4.6	107
17	Use of Human Induced Pluripotent Stem Cellâ€“Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association. Circulation Research, 2019, 125, e75-e92.	2.0	103
18	Lymphoangiocrine signals promote cardiac growth and repair. Nature, 2020, 588, 705-711.	13.7	103

#	Article	IF	Citations
19	Use of human induced pluripotent stem cellâ€“derived cardiomyocytes to assess drug cardiotoxicity. Nature Protocols, 2018, 13, 3018-3041.	5.5	102
20	Sirtuin 2 regulates cellular iron homeostasis via deacetylation of transcription factor NRF2. Journal of Clinical Investigation, 2017, 127, 1505-1516.	3.9	101
21	Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems. Annual Review of Pharmacology and Toxicology, 2018, 58, 83-103.	4.2	89
22	Characterization of the molecular mechanisms underlying increased ischemic damage in the <i>aldehyde dehydrogenase 2</i> genetic polymorphism using a human induced pluripotent stem cell model system. Science Translational Medicine, 2014, 6, 255ra130.	5.8	84
23	Negligible-Cost and Weekend-Free Chemically Defined Human iPSC Culture. Stem Cell Reports, 2020, 14, 256-270.	2.3	80
24	Induced Pluripotent Stem Cells from Familial Alzheimer's Disease Patients Differentiate into Mature Neurons with Amyloidogenic Properties. Stem Cells and Development, 2014, 23, 2996-3010.	1.1	75
25	A Human Pluripotent Stem Cell Surface N-Glycoproteome Resource Reveals Markers, Extracellular Epitopes, and Drug Targets. Stem Cell Reports, 2014, 3, 185-203.	2.3	73
26	Generation of Human iPSCs from Human Peripheral Blood Mononuclear Cells Using Non-integrative Sendai Virus in Chemically Defined Conditions. Methods in Molecular Biology, 2013, 1036, 81-88.	0.4	72
27	Derivation of Highly Purified Cardiomyocytes from Human Induced Pluripotent Stem Cells Using Small Molecule-modulated Differentiation and Subsequent Glucose Starvation. Journal of Visualized Experiments, 2015, , .	0.2	68
28	Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-Î² and Cardiac Fibrosis. Circulation, 2017, 136, 664-679.	1.6	64
29	Genetic and Epigenetic Regulation of Human Cardiac Reprogramming and Differentiation in Regenerative Medicine. Annual Review of Genetics, 2015, 49, 461-484.	3.2	63
30	Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?. , 2016, 168, 113-125.		61
31	High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry. Journal of Visualized Experiments, 2014, , 52010.	0.2	56
32	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nature Genetics, 2022, 54, 232-239.	9.4	55
33	Novel codon-optimized mini-intronic plasmid for efficient, inexpensive and xeno-free induction of pluripotency. Scientific Reports, 2015, 5, 8081.	1.6	51
34	Accurate nanoelectrode recording of human pluripotent stem cell-derived cardiomyocytes for assaying drugs and modeling disease. Microsystems and Nanoengineering, 2017, 3, 16080.	3.4	49
35	Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity. Circulation, 2022, 145, 279-294.	1.6	46
36	Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism. European Heart Journal, 2015, 36, 806-816.	1.0	40

#	Article	IF	Citations
37	Acute CD47 Blockade During Ischemic Myocardial Reperfusion Enhances Phagocytosis-Associated Cardiac Repair. JACC Basic To Translational Science, 2017, 2, 386-397.	1.9	40
38	Engraftment of human embryonic stem cell derived cardiomyocytes improves conduction in an arrhythmogenic in vitro model. Journal of Molecular and Cellular Cardiology, 2012, 53, 15-23.	0.9	37
39	Hematopoiesis from Human Embryonic Stem Cells: Overcoming the Immune Barrier in Stem Cell Therapies. Stem Cells, 2006, 24, 815-824.	1.4	36
40	RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. Cell Stem Cell, 2021, 28, 2076-2089.e7.	5.2	36
41	Highly Efficient Directed Differentiation of Human Induced Pluripotent Stem Cells into Cardiomyocytes. Methods in Molecular Biology, 2013, 997, 149-161.	0.4	35
42	Modeling Cardiovascular Diseases with Patient-Specific Human Pluripotent Stem Cell-Derived Cardiomyocytes. Methods in Molecular Biology, 2015, 1353, 119-130.	0.4	35
43	Genetic Mosaicism in Calmodulinopathy. Circulation Genomic and Precision Medicine, 2019, 12, 375-385.	1.6	33
44	Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	33
45	Stage-specific Effects of Bioactive Lipids on Human iPSC Cardiac Differentiation and Cardiomyocyte Proliferation. Scientific Reports, 2018, 8, 6618.	1.6	32
46	Multi-cellular interactions sustain long-term contractility of human pluripotent stem cell-derived cardiomyocytes. American Journal of Translational Research (discontinued), 2014, 6, 724-35.	0.0	32
47	Challenges and strategies for generating therapeutic patient-specific hemangioblasts and hematopoietic stem cells from human pluripotent stem cells. International Journal of Developmental Biology, 2010, 54, 965-990.	0.3	29
48	Silencing of <i>MYH7</i> ameliorates disease phenotypes in human iPSC-cardiomyocytes. Physiological Genomics, 2020, 52, 293-303.	1.0	29
49	Genetic Variants Associated with Therapy-Related Cardiomyopathy among Childhood Cancer Survivors of African Ancestry. Cancer Research, 2021, 81, 2556-2565.	0.4	24
50	Association of <i>GSTM1</i> null variant with anthracyclineâ€related cardiomyopathy after childhood cancerâ€"A Children's Oncology Group ALTE03N1 report. Cancer, 2020, 126, 4051-4058.	2.0	23
51	Targeting the Microtubule EB1-CLASP2 Complex Modulates Na _V 1.5 at Intercalated Discs. Circulation Research, 2021, 129, 349-365.	2.0	23
52	hiPSCs in cardio-oncology: deciphering the genomics. Cardiovascular Research, 2019, 115, 935-948.	1.8	21
53	Pluripotent stem cell heterogeneity and the evolving role of proteomic technologies in stem cell biology. Proteomics, 2011, 11, 3947-3961.	1.3	20
54	Human embryonic stem cells as a model for nutritional programming: An evaluation. Reproductive Toxicology, 2005, 20, 353-367.	1.3	18

#	Article	IF	Citations
55	Late onset heart failure after childhood chemotherapy. European Heart Journal, 2019, 40, 798-800.	1.0	18
56	GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cellâ€“Derived Cardiomyocytes. Molecular Pharmacology, 2020, 98, 540-547.	1.0	17
57	Structural and Functional Characterization of a Na _v 1.5-Mitochondrial Couplon. Circulation Research, 2021, 128, 419-432.	2.0	15
58	Are These Cardiomyocytes? Protocol Development Reveals Impact of Sample Preparation on the Accuracy of Identifying Cardiomyocytes by Flow Cytometry. Stem Cell Reports, 2019, 12, 395-410.	2.3	14
59	Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity. Journal of Cardiovascular Translational Research, 2020, 13, 377-389.	1.1	11
60	The future role of pharmacogenomics in anticancer agent-induced cardiovascular toxicity. Pharmacogenomics, 2018, 19, 79-82.	0.6	10
61	Patient-specific pluripotent stem cells in doxorubicin cardiotoxicity: A new window into personalized medicine. Progress in Pediatric Cardiology, 2014, 37, 23-27.	0.2	9
62	Derivation and characterisation of the human embryonic stem cell lines, NOTT1 and NOTT2. In Vitro Cellular and Developmental Biology - Animal, 2010, 46, 367-375.	0.7	8
63	Cellular model systems to study cardiovascular injury from chemotherapy. Journal of Thrombosis and Thrombolysis, 2021, 51, 890-896.	1.0	8
64	Precise and Cost-Effective Nanopore Sequencing for Post-GWAS Fine-Mapping and Causal Variant Identification. IScience, 2020, 23, 100971.	1.9	7
65	Doxorubicin induces caspase-mediated proteolysis of KV7.1. Communications Biology, 2018, 1, 155.	2.0	5
66	Unraveling Difficult Answers: From Genotype to Phenotype in Coronary Artery Disease. Cell Stem Cell, 2019, 24, 203-205.	5.2	5
67	An updated protocol for the cost-effective and weekend-free culture of human induced pluripotent stem cells. STAR Protocols, 2021, 2, 100213.	0.5	5
68	Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity. Pharmacogenomics, 2021, 22, 41-54.	0.6	4
69	A Novel Locus on 6p21.2 for Cancer Treatmentâ€“Induced Cardiac Dysfunction Among Childhood Cancer Survivors. Journal of the National Cancer Institute, 2022, 114, 1109-1116.	3.0	4
70	Pluripotent Stem Cell Modeling of Anticancer Therapyâ€“Induced Cardiotoxicity. Current Cardiology Reports, 2020, 22, 56.	1.3	2
71	Doxorubicin-Induced Ascension of Resident Cardiac Macrophages. Circulation Research, 2020, 127, 628-630.	2.0	1
72	Generating a Costâ€Effective, Weekendâ€Free Chemically Defined Human Induced Pluripotent Stem Cell (hiPSC) Culture Medium. Current Protocols in Stem Cell Biology, 2020, 53, e110.	3.0	1

#	Article	IF	Citations
73	Letter by Costantine et al Regarding Article, â€œPravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsiaâ€. Circulation, 2022, 145, e115-e116.	1.6	1
74	Generation and Application of Human Pluripotent Stem Cell-Derived Cardiomyocytes. Cardiac and Vascular Biology, 2017, , 67-106.	0.2	0
75	Prime time for doxorubicin-induced cardiotoxicity genetic testing. Pharmacogenomics, 2022, 23, 335-338.	0.6	0